Vol. 16 No. 32 (2020)

Artículos

Health comorbidities and their effects on people with SARS-Cov-2 in Mexico

Published 2020-10-28 — Updated on 2020-10-28

  • Brenda Coutiño
    • ,
  • Oscar A. Martínez-Martínez

Brenda Coutiño
Universidad Iberoamericana image/svg+xml , Ibero American University image/svg+xml , Universidad Iberoamericana image/svg+xml

Oscar A. Martínez-Martínez
Universidad Iberoamericana image/svg+xml , Ibero American University image/svg+xml , Universidad Iberoamericana image/svg+xml

Abstract

As the COVID-19 pandemic evolves, certain comorbidities have been found to be related to this disease. These factors become important to define the group considered vulnerable, as well as the measures (confinement or distancing) and treatments that must be used in accordance with the protocols established by governments. Using data from the General Directorate of Epidemiology of the Federal Government, at the cut-off of August 5, a binomial logit regression model was applied to estimate the effects of comorbidities in patients infected with the SAR-CoV-2 virus, and determine which factors are most likely to occur associated with the risk of death from this disease. The results reveal that suffering from diabetes, as well as the registration of other comorbidities, increases the probability of death, while age is a variable that potentially increases it. The findings show the importance of promoting and redesigning preventive health policies that include substantial changes in the way of life of patients and their families as one of the ways to improve their well-being.

Keywords

SARS-CoV-2, comorbidities, diabetes, age, poverty

PDF (Spanish)

References

  1. Agresti, A. (1991). Categorical data analysis (Vol. 482). John Wiley & Sons, Inc. New Jersey.
  2. Atkins, J. L., Masoli, J. A., Delgado, J., Pilling, L. C., Kuo, C.-L. C., Kuchel, G. & Melzer, D. (2020). Preexisting comorbidities predicting severe COVID-19 in older adults in the UK Biobank community cohort. medRxiv. https://doi.org/10.1101/2020.05.06.20092700
  3. Bellido, V. & Pérez, A. (2020). Consecuencias de la COVID-19 sobre las personas con diabetes. Endocrinologıea, Diabetes y Nutrición. https://doi.org/10.1016/j.endinu.2020.04.001
  4. BID. (2020). Los problemas de salud, la pobreza y los desafíos de COVID-19 en América Latina y el Caribe. Banco Interamericano de Desarrollo. https://blogs.iadb.org/ideas-que-cuentan/es/losproblemas-de-salud-la-pobreza-y-los-desafios-de-covid-19-en-america-latina-y-el-caribe/
  5. Bliss, C. I. (1934). The method of probits—a correction. Science, 79 (2053), 409-410.
  6. Caughey, G. E., Vitry, A. I., Gilbert, A. L. & Roughead, E. E. (2008). Prevalence of comorbidity of chronic diseases in Australia. BMC public health, 8 (1), 221. https://doi.org/10.1186/1471-2458-8-221
  7. Clark, A., Jit, M., Warren-Gash, C., Guthrie, B., Wang, H. H., Mercer, S. W., Sanderson, C., McKee, M., Troeger, C., Ong, K. L. et al. (2020). Global, regional, and national estimates of the population at increased risk of severe COVID-19 due to underlying health conditions in 2020: a modelling study. The Lancet Global Health, 8 (8), e1003-e1017. https://doi.org/10.1016/S2214-109X(20)30264-3
  8. Clay, C. C., Donart, N., Fomukong, N., Knight, J. B., Overheim, K., Tipper, J., Van Westrienen, J., Hahn, F. & Harrod, K. S. (2014). Severe acute respiratory syndrome-coronavirus infection in aged nonhuman primates is associated with modulated pulmonary and systemic immune responses. Immunity & Ageing, 11 (1), 4. https://doi.org/10.1186/1742-4933-11-4
  9. England., P. H. (2020). Guidance on Shielding and Protecting People Defined on Medical Grounds as Extremely Vulnerable from COVID-19. https://rb.gy/lh5p9s
  10. Guan, W.-j., Liang, W.-h., Zhao, Y., Liang, H.-r., Chen, Z.-s., Li, Y.-m., Liu, X.-q., Chen, R.-c., Tang, C.-l.,Wang, T. et al. (2020). Comorbidity and its impact on 1590 patients with Covid-19 in China: A Nationwide Analysis. European Respiratory Journal, 55 (5). https://doi.org/10.1183/13993003.00547-2020
  11. Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X. et al. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The lancet, 395 (10223), 497-506. https://doi.org/10.1016/S0140-6736(20)30183-5
  12. Hui, D. S., Azhar, E. I., Madani, T. A., Ntoumi, F., Kock, R., Dar, O., Ippolito, G., Mchugh, T. D., Memish, Z. A., Drosten, C. et al. (2020). The continuing 2019-nCoV epidemic threat of novel coronaviruses to global health—The latest 2019 novel coronavirus outbreak in Wuhan, China. International Journal of Infectious Diseases, 91, 264-266. https://www.ijidonline.com/article/S1201-9712(20)30011-4/abstract
  13. Lau, D., Eurich, D. T., Majumdar, S. R., Katz, A. & Johnson, J. A. (2013). Effectiveness of influenza vaccination in working-age adults with diabetes: a population-based cohort study. Thorax, 68 (7), 658-663. http://dx.doi.org/10.1136/thoraxjnl-2012-203109
  14. Moni, M. A. & Li`o, P. (2014). Network-based analysis of comorbidities risk during an infection: SARS and HIV case studies. BMC bioinformatics, 15 (1), 333. https://doi.org/10.1186/1471-2105-15-333
  15. Roncon, L., Zuin, M., Rigatelli, G. & Zuliani, G. (2020). Diabetic patients with COVID-19 infection are at higher risk of ICU admission and poor short-term outcome. Journal of Clinical Virology, 104354. https://doi.org/10.1016/j.jcv.2020.104354
  16. Salvador-Ballesteros, M. (2015). Promedio de los efectos marginales e interacciones en las regresiones logísticas binarias [INCASI Working Paper Series is an online publication under]. https://ddd.uab.cat/record/189811
  17. Vivanco-Hidalgo, R. (2020). Generalitat de Catalunya. Agencia de Qualitat i Avaluació Sanitaries de Catalunya Edita: Agencia de Qualitat i Avaluació Sanitaries de Catalunya (1.a ed.).
  18. World Health Organization. (2020a). CDC guidance on individuals at higher risk of severe COVID-19 disease. https://rb.gy/lwbqlw
  19. World Health Organization. (2020b). Global Surveillance for human infection with coronavirus disease (COVID-19), 2020. https://rb.gy/erfdbj
  20. World Health Organization. (2020c). guidance on COVID-19 and NCDs, 2020. https://rb.gy/8rcqsj
  21. World Health Organization. (2020d). Preguntas y respuestas sobre la enfermedad por coronavirus (COVID-
  22. . https://www.who.int/es/emergencies/diseases/novel-coronavirus-2019/advice-for-public/q-a-coronaviruses?gclid=Cj0KCQjwrIf3BRD1ARIsAMuugNs7y6ukWOuTjeXsv3%5CqrKOEHtrladzY2i--E72N%5CVuxZIN59-MJ%5C e0aAttpEALw%5C wcB
  23. World Health Organization. (2020e). Public Health England (PHE) definition of individuals at increased risk of severe COVID-19 illness. https://rb.gy/dlkcze
  24. Yang, J., Zheng, Y., Gou, X., Pu, K., Chen, Z., Guo, Q., Ji, R., Wang, H., Wang, Y. & Zhou, Y. (2020). Prevalence of comorbidities and its effects in patients infected with SARS-CoV-2: a systematic review and meta-analysis. International Journal of Infectious Diseases, 94, 91-95. https://doi.org/10.1016/j.ijid.2020.03.017